Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

NRx Pharmaceuticals, Inc. (NRXP)

1.23   -0.02 (-1.6%) 01-27 16:00
Open: 1.22 Pre. Close: 1.25
High: 1.26 Low: 1.1801
Volume: 246,692 Market Cap: 83(M)

Technical analysis

as of: 2023-01-27 4:46:39 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.64     One year: 1.92
Support: Support1: 1.17    Support2: 1.02
Resistance: Resistance1: 1.4    Resistance2: 1.64
Pivot: 1.26
Moving Average: MA(5): 1.25     MA(20): 1.23
MA(100): 0.99     MA(250): 1.3
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 49.4     %D(3): 53.8
RSI: RSI(14): 50.2
52-week: High: 3.53  Low: 0.49
Average Vol(K): 3-Month: 393 (K)  10-Days: 305 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NRXP ] has closed above bottom band by 33.7%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.26 - 1.27 1.27 - 1.28
Low: 1.16 - 1.17 1.17 - 1.18
Close: 1.22 - 1.23 1.23 - 1.24

Company Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Headline News

Thu, 19 Jan 2023
NRXP stock gains on FDA comments regarding lead asset ... - Seeking Alpha

Thu, 05 Jan 2023
NRx Pharmaceuticals: A Speculative, Binary Play (NASDAQ:NRXP) - Seeking Alpha

Tue, 03 Jan 2023
XPEV, LI and BILI are among pre market gainers - Seeking Alpha

Tue, 03 Jan 2023
Health Care Sector Update for 01/03/2023: XLV, VHT, TXMD, SY ... - Nasdaq

Tue, 03 Jan 2023
NRXP stock gains as Phase 3 trial for bipolar candidate starts ... - Seeking Alpha

Mon, 05 Dec 2022
NRx Pharmaceuticals Announces the Appointment of Carrie M ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 68 (M)
Shares Float 40 (M)
% Held by Insiders 44.1 (%)
% Held by Institutions 7.1 (%)
Shares Short 1,520 (K)
Shares Short P.Month 1,310 (K)

Stock Financials

EPS -6.25
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.25
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -156
Return on Equity (ttm) -474.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.3
Qtrly Earnings Growth 0
Operating Cash Flow -43 (M)
Levered Free Cash Flow -79 (M)

Stock Valuations

PE Ratio -0.2
PEG Ratio 0
Price to Book value 4.92
Price to Sales 0
Price to Cash Flow -1.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.